Phosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric Cancer

Guo-dong Cao, Xing-yu Xu, Jia-wei Zhang, Bo Chen, Mao-ming Xiong

1 Anhui Medical University, Hefei, Anhui, China, 2 Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

☯ These authors contributed equally to this work.
* chenbo831116@163.com (BC); ayfyxmm@163.com (MMX)

Abstract

Aims
The mammalian target of rapamycin (mTOR) and phosphorylated mTOR (p-mTOR) occurring downstream in the PI3K/Akt/mTOR pathway, are regarded as potential prognostic markers for gastric cancer (GC). However, the prognostic value of mTOR/p-mTOR expression remains controversial. In this study, we determined the expression of mTOR, p-mTOR, p70S6K, and p-p70S6K in GC, and investigated the correlation between their overexpression, clinicopathological parameters, and overall survival (OS).

Methods
The expression of mTOR, p-mTOR, p70S6K, and p-p70S6K was examined in 120 GC patients by immunohistochemistry (IHC). The association of protein expression with clinicopathological features and OS was explored. The p-mTOR expression was detected in normal, adjacent, and GC tissues using Western blot. Eligible studies retrieved from PubMed, Ovid, Web of Science and Cochrane databases, were reviewed in this meta-analysis.

Results
IHC showed that the rates of expression of the signal transduction molecules mTOR, p-mTOR, p70S6K and p-p70S6K in GC were 60.8%, 54.2%, 53.3% and 53.3%, respectively. Overexpression of mTOR and p70S6K showed no significant association with clinical variables. Expression of p-mTOR was significantly associated with differentiation ($P < 0.01$), depth of invasion ($P < 0.01$), lymph node metastasis ($P = 0.04$) and TNM stage ($P = 0.02$). Expression of p-p70S6K was associated with differentiation ($P = 0.006$), depth of invasion ($P < 0.001$), and TNM stage ($P = 0.02$). In survival analysis, differentiation, depth of invasion, lymph node metastasis and TNM stage were not related to OS (all $P > 0.05$). Furthermore, p-mTOR and p-p70S6K expression, but not mTOR and p70S6K, were tightly associated with OS of GC patients ($P = 0.006$ and $P < 0.001$, respectively). In Western blot, p-mTOR was significantly higher in GC tissues than in normal and adjacent tissues. In the present
meta-analysis, mTOR overexpression showed no relationship with any clinicopathological variables. However, p-mTOR was correlated with depth of invasion, and TNM stage (all \( P < 0.05 \)), and its overexpression was associated with a shorter survival time (\( P < 0.001 \)).

**Conclusion**

The results suggest that p-mTOR is a more valuable prognostic factor than mTOR in GC.

---

**Introduction**

Gastric cancer (GC) is one of the most common cancers. According to the Global Cancer Statistics, 2012 [1], GC ranks sixth among all tumors in terms of the standardized incidence. About 60% of the new GC cases occur in eastern Asia [2], especially China. Tumor stage is a key factor for survival of GC patients. However, due to delayed diagnosis [3], most GC patients are at an advanced stage of cancer or distant metastasis. Despite palliative surgery, the 5–year overall survival (OS) is poor, with the median OS less than 1 year [4]. After surgical resection, the prognosis of patients with advanced GC is not ideal. Therefore, a novel prognostic biomarker for GC is necessary.

The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is known to be frequently activated in several types of cancer and is essential for cancer cell survival, proliferation, angiogenesis, and resistance to chemotherapy [5–6]. Ligand binding to receptors triggers tumor growth and progression mediated via Akt, a downstream effector of PI3K pathway [7]. Moreover, mTOR, a serine/threonine protein kinase expressed in the PI3K pathway, acts as a downstream mediator in the PI3K/Akt signaling pathway [8]. It is a key regulator of eukaryotic cell growth and plays a critical role in regulating several cellular functions, including proliferation, differentiation, tumorigenesis, angiogenesis, autophagy, and apoptosis [9–10]. The mTOR activity is mediated by p-AKT. The p-mTOR expression is significantly correlated with the prognosis of gastrointestinal tumors, such as GC [11] and colorectal cancer [12], leading to decreased survival time.

Few studies have investigated the correlation between mTOR, p-mTOR, and prognostic variables comprehensively in GC. The aim of the present study was to determine the expression of mTOR and p-mTOR in GC and its correlation with clinicopathological characteristics and OS.

**Materials and Methods**

**Patients and samples**

GC tissue samples (120) were collected from patients who underwent total or subtotal gastrectomy at the First Affiliated Hospital of Anhui Medical University from 2010 to 2011, without receiving preoperative chemoradiotherapy. The patients’ age, sex, tumor location, tumor size, differentiation, depth of invasion, lymph node metastasis, distant metastasis, and TNM stage were determined by a review of their medical records. Each tumor sample was classified according to the tumor–node–metastasis (TNM) classification advocated by the International Union against Cancer [13]. Follow-up duration was determined from the date of surgical treatment until the event (death or recurrence) or censoring. The study was approved by the ethics committee of the University.
Immunohistochemistry

The tissue samples were fixed in 10% neutral formalin and embedded in paraffin for sectioning and staining according to the manufacturer’s instructions. The 3- to 5-μm-thick tissue sections were deparaffinized and hydrated in xylene and serially diluted ethanol, respectively. The endogenous peroxidase was blocked by incubation with 3% H₂O₂ for 10 min. Antigen retrieval was performed in a microwave oven using citrate solution. Subsequently, the tissue sections were incubated with the appropriate primary antibody for 12 h to 16 h at 4˚C. The slides were washed three times in phosphate-buffered saline (PBS) and incubated with secondary antibody for 20 min. After three further washes in PBS, diaminobenzidine tetrahydrochloride (DAB) was used before counter staining with hematoxylin. The following primary antibodies were used: mTOR (1:150), p-mTOR (1:200) (Abcam, Cambridge, UK), p70S6K (1:150) (Abcam, Cambridge, UK) and p-p70S6K (1:100) (Elabscience, Wuhan, China).

Evaluation of immunohistochemistry

The results of immunohistochemical staining for mTOR and p-mTOR were evaluated by two independent investigators according to a semiquantitative grading system based on the proportion of stained cells and their intensity [14]. The results of immunohistochemical staining were also evaluated under similar scoring criteria. Staining intensity was scored as: 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The percentage of positive epithelial cells was scored as: 0 (no staining), 1 (<1/3 staining), 2 (1/3 to 2/3 staining), and 3 (>2/3 staining). A histological score was generated as the product of intensity and the percentage of positive epithelial cells. The results of immunostaining were divided into two groups, with 0–2 score regarded as negative and >2 score considered as positive expression.

Protein extraction and Western blot

Total protein was extracted from the normal mucosa, para-carcinoma and corresponding tumor tissues of 10 GC patients using RIPA lysis buffer (Beyotime, Shanghai, China). The protein concentration was quantified using the Enhanced BCA Protein Assay Kit. The equivalent proteins in each pair of specimens were separated by SDS–PAGE on 12% polyacrylamide gels and electrotransferred to polyvinylidene fluoride membranes. After blocking in TBST (Tris-buffered saline/Tween-20 buffer) containing 5% skim milk for 1 h at room temperature, the membrane was incubated in TBST solution containing anti-p-mTOR (1: 2000, Abcam, Cambridge, UK) overnight at 4˚C. After washing three times in TBST, the membranes were incubated with the corresponding secondary antibodies in TBST along with 3% skim milk powder for 1 h at room temperature. After three washing steps in TBST, the band intensity was measured using the BandScan software. The p-mTOR band intensities were normalized to GAPDH signals.

Statistical analysis

Statistical analyses were performed using the SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Associations between variables were examined using Pearson’s chi-squareand, Continuity correction Fisher’s exact tests. Survival curves were calculated by the Kaplan–Meier method, and the statistical significance was evaluated using the log-rank test. Results were considered statistically significant if P<0.05.
Meta-Analysis

Aims

Because of a small number of patients, a meta-analysis was conducted to confirm the previous results of IHC and survival analysis, and fully investigate whether exist relationship between mTOR, p-mTOR and clinicopathological parameters, OS through meta-analysis.

Methods

Relevant articles were searched from PubMed, Ovid, Web of Science, and Cochrane from Feb 2002 to Jul 2016. The search terms used were: (“mTOR” OR “the mammalian target of Rapamycin” OR “p-mTOR” OR “phosphorylated mTOR” OR “phosphorylated mammalian target of Rapamycin”) AND (“gastric” OR “stomach” OR “cardia” OR “gastrointestinal”) AND (“adenocarcinoma” OR “carcinoma” OR “cancer” OR “tumour” OR “neoplasm” OR “tumor”). The full texts of the studies were reviewed to determine eligibility based on the inclusion criteria (Fig 1).

The full texts of the studies were read and selected if they met the following inclusion criteria: (1) GC was identified, (2) expression of proteins was evaluated by IHC, (3) clinicopathological parameters and OS were available, (4) standards to assess the protein expression was consistent across different studies, and (5) the article was published in English and Chinese.

Two investigators (Guo-dong Cao and Xing-yu Xu) extracted the data independently based on consensus. The following data were extracted: first author’s name, year of publication, total number of patients, clinicopathological parameters, and survival time. During the data extraction, any disagreements were resolved by a third investigator (Bo Chen) and a consensus was reached. Two investigators (Guo-dong Cao and Xing-yu Xu) assessed the quality of included studies using the Newcastle–Ottawa scale [15].

All the statistical analyses were performed using the STATA software (version 11.0, StataCorp LP, College Station, TX, USA). The crude odds ratio (OR) and 95% confidence interval (CI) were used to estimate the strength of the association between mTOR, p-mTOR and clinicopathological parameters of GC patients. Risk ratios (RR) and 95% CIs were used in this meta-analysis to estimate the association of the status of pathway-related proteins with OS. $I^2$ value, which indicated the percentage of total variation across studies, was used to assess statistical heterogeneity. Random-effects models ($I^2 > 50\%$ or $P < 0.1$) of analysis were used if significant heterogeneity was detected. Otherwise, fixed-effects models were used. Begg’s rank correlation and Egger’s weighted regression methods were used to determine potential publication bias ($P < 0.05$ indicates statistically significant publication bias).

Results

Expression of mTOR, p-mTOR, p70S6k and p-p70S6K in GC

The IHC images were demonstrated in Figure 2a (Fig 2a). According to the IHC results, mTOR and p-mTOR were highly expressed in GC tissue (Table 1). The overall rate of mTOR overexpression in 120 GC patients was 60.8%, and the overall rate of p-mTOR overexpression in 120 GC patients was 54.2%. IHC showed that the concurrent rate of p70S6k and p-p70S6K expression in GC was 53.3%. No significant difference was found between this study and previous studies (Table 2). In addition, according to Spearman correlation analysis, mTOR and p-mTOR were both significantly linked to p-p70S6K expression ($P = 0.002$ and $P < 0.001$, respectively, Table 3).

As one of the major downstream proteins of PI3K/Akt/mTOR pathway, the activation of mTOR was detected in 10 paired GC samples including adjacent and normal tissues by
Western blot. The p-mTOR expression was significantly higher in GC tissues indicating that it was probably related to GC tumorigenesis (Fig 2b).

Association between mTOR, p-mTOR, p70S6k, and p-p70S6K expression and relevant parameters

As shown in Tables 1 and 2, the overexpression of mTOR was not significantly associated with sex, tumor size, differentiation, and tumor location, depth of invasion, and lymph node metastasis, or distant metastasis. However, mTOR expression was significant correlated with TNM stage ($P = 0.03$). The p70S6K expression showed no significant association with any other clinical parameters, except depth of invasion ($P = 0.03$). Meanwhile, in the present study, p-mTOR was significantly linked to differentiation ($P < 0.01$), depth of invasion ($P < 0.01$), lymph node metastasis ($P = 0.04$) and TNM stage ($P = 0.02$). The p-p70S6K expression was associated with differentiation ($P = 0.006$), depth of invasion ($P < 0.001$), and TNM stage ($P = 0.02$). The positive expression of p-mTOR and p-p70S6K suggested the possibility of poor differentiation, deeper invasion, positive lymph node metastasis and delayed TNM stage.

Survival analysis

Survival analysis was demonstrated in Fig 2. OS was not related to differentiation (Log-Rank test: $P = 0.38$, Fig 3a), depth of invasion (Log-Rank test: $P = 0.20$, Fig 3b), lymph node
metastasis (Log-Rank test: \( P = 0.47 \), Fig 3c) or TNM stage (Log-Rank test: \( P = 0.41 \), Fig 3d) in GC patients. As shown in Fig 3e, no association was found between mTOR and OS (Log-Rank test: \( P = 0.43 \)). GC patients with p-mTOR overexpression showed significantly shorter overall survival rates than p-mTOR negative GC patients (Log-Rank test: \( P = 0.006 \)) (Fig 3f). Further, p-p70S6K expression was significantly associated with OS of GC patients (Log-Rank test: \( P < 0.001 \)) (Fig 3g). However, no such association was found between OS and p70S6K (Log-Rank test: \( P = 0.28 \)) (Fig 3h).

**Univariate and multivariate analysis of OS**

The prognostic relevance of mTOR, p-mTOR and several clinical factors was evaluated using univariate and multivariate analysis, respectively. In univariate analysis, none of the clinical factors or mTOR was associated with OS, except for p-mTOR (Hazard ratio = 1.88, 95% CI: 1.19–2.99, \( P = 0.01 \), Table 4) and p-p70S6K (Hazard ratio = 2.64, 95% CI: 1.65–4.23, \( P < 0.001 \), Table 4).
### Table 1. Association between the clinicopathological parameters and mTOR, p-mTOR expression in 120 cases of gastric cancer.

| Variable          | Total patients | mTOR-positive | mTOR-negative | P value | p-mTOR-positive | p-mTOR-negative | P value |
|------------------|----------------|---------------|---------------|---------|----------------|----------------|---------|
| Sex              | Male           | 80            | 50            | 30      | 0.60           | 46             | 34      | 0.30   |
|                  | Female         | 40            | 23            | 17      | 0.60           | 19             | 21      |        |
| Age              | <60y           | 49            | 21            | 28      | <0.01          | 26             | 23      | 0.84   |
|                  | >60y           | 71            | 52            | 19      | 0.84           | 39             | 32      |        |
| Tumor size       | <3cm           | 15            | 9             | 6       | 0.58           | 9              | 6       | 0.63   |
|                  | >3cm           | 105           | 64            | 41      | 0.58           | 56             | 49      |        |
| Differentiation  | Well/moderate  | 102           | 60            | 42      | 0.28           | 49             | 53      | <0.01  |
|                  | Poor           | 18            | 13            | 5       | 0.28           | 16             | 2       |        |
| Tumor location   | Upper/Medium   | 77            | 49            | 28      | 0.40           | 43             | 34      | 0.62   |
|                  | Low            | 43            | 24            | 19      | 0.40           | 22             | 21      |        |
| Depth of invasion| T1+T2          | 22            | 10            | 12      | 0.10           | 6              | 16      | <0.01  |
|                  | T3+T4          | 98            | 63            | 35      | 0.10           | 59             | 39      |        |
| LN metastasis    | N0             | 25            | 12            | 13      | 0.14           | 9              | 16      | 0.04   |
|                  | N1+N2+N3       | 95            | 61            | 34      | 0.14           | 56             | 39      |        |
| Metastasis       | M0             | 114           | 70            | 44      | 0.58           | 63             | 51      | 0.53   |
|                  | M1             | 6             | 3             | 3       | 0.58           | 2              | 4       |        |
| TNM stage        | I+II           | 33            | 15            | 18      | 0.03           | 12             | 21      | 0.02   |
|                  | III+IV         | 87            | 58            | 29      | 0.03           | 53             | 34      |        |

LN metastasis: lymph node metastasis. TNM stages are based on tumor-node-metastasis classification advocated by International Union against Cancer.

doi:10.1371/journal.pone.0168085.t001

### Table 2. Association between the clinicopathological parameters and p70S6K, p-p70S6K expression in 120 cases of gastric cancer.

| Variable          | Total patients | p70S6K-positive | p70S6K-negative | P value | p-p70S6K-positive | p-p70S6K-negative | P value |
|------------------|----------------|-----------------|-----------------|---------|------------------|------------------|---------|
| Sex              | Male           | 80              | 45              | 35      | 0.37             | 43               | 37      | 0.90   |
|                  | Female         | 40              | 19              | 21      | 0.37             | 21               | 19      |        |
| Age              | <60y           | 49              | 21              | 28      | 0.06             | 24               | 25      | 0.43   |
|                  | >60y           | 71              | 43              | 28      | 0.06             | 40               | 31      |        |
| Tumor size       | <3cm           | 15              | 6               | 9       | 0.27             | 7                | 8       | 0.58   |
|                  | >3cm           | 105             | 58              | 47      | 0.27             | 57               | 48      |        |
| Differentiation  | Well/moderate  | 102             | 55              | 47      | 0.76             | 49               | 53      | 0.006  |
|                  | Poor           | 18              | 9               | 9       | 0.76             | 15               | 3       |        |
| Tumor location   | Upper/Medium   | 77              | 40              | 37      | 0.68             | 41               | 36      | 0.98   |
|                  | Low            | 43              | 24              | 19      | 0.68             | 23               | 20      |        |
| Depth of invasion| T1+T2          | 22              | 7               | 15      | 0.03             | 4                | 18      | <0.001 |
|                  | T3+T4          | 98              | 57              | 41      | 0.03             | 60               | 38      |        |
| LN metastasis    | N0             | 25              | 15              | 10      | 0.45             | 11               | 14      | 0.293  |
|                  | N1+N2+N3       | 95              | 49              | 46      | 0.45             | 53               | 42      |        |
| Metastasis       | M0             | 114             | 62              | 52      | 0.42             | 61               | 53      | 1.00   |
|                  | M1             | 6               | 2               | 4       | 0.42             | 3                | 3       |        |
| TNM stage        | I+II           | 33              | 15              | 18      | 0.29             | 12               | 21      | 0.02   |
|                  | III+IV         | 87              | 49              | 38      | 0.29             | 52               | 35      |        |

LN metastasis: lymph node metastasis. TNM stages are based on tumor-node-metastasis classification advocated by International Union against Cancer.

doi:10.1371/journal.pone.0168085.t002
Table 2). The multivariate Cox proportional hazards model showed a significant correlation between p-p70S6K expression and OS (Hazard ratio = 3.00, 95% CI: 1.45–6.20, \( P = 0.003 \), Table 2).

Study characteristics of meta-analysis

After reviewing the abstracts and full texts, three studies of mTOR [16–18] and seven studies involving p-mTOR [11, 18–23] overexpression in GC met the inclusion criteria and were selected, respectively (Fig 3). The characteristics of the eligible studies are listed in Table 5. The study samples were analyzed using IHC and the standards for assessment were almost consistent. The mTOR positive expression in the eligible studies ranged from 51.5% to 54.6%, and the total rate of mTOR overexpression in GC patients of all the studies was 53.9% (817/1517). The rate of p-mTOR overexpression in GC ranged from 31.6% to 74.0%, and the overall rate was 48.3% (1387/2874).

![Table 3. Spearman correlation analysis between mTOR/p-mTOR and p70S6K/p-p70S6K.](image1)

| mTOR                  | Spearman correlation | \( P \) value | p-mTOR                  | Spearman correlation | \( P \) value |
|-----------------------|----------------------|---------------|-------------------------|----------------------|---------------|
| p70S6K                | 0.023                | 0.802         | p-p70S6K                | 0.029                | 0.751         |
| p-p70S6K              | 0.276                | 0.002         |                         | 0.481                | <0.001        |

doi:10.1371/journal.pone.0168085.t003

![Fig 3. Kaplan-Meier survival curves for overall survival of 98 gastric cancer patients.](image2)

**Fig 3.** Kaplan-Meier survival curves for overall survival of 98 gastric cancer patients. Differentiation (3a), depth of invasion (3b), lymph node metastasis (3c), TNM stage (3d), mTOR (3e) and p70S6K (3g) has no relationship with overall survival rate, all \( P > 0.05 \) analyzed by Log-Rank test. While the most interesting phenomenon is that p-mTOR (3f) and p-p70S6K (3h) overexpression are significantly associated with overall survival rate of GC patients, however, mTOR has no relationship with overall survival.

doi:10.1371/journal.pone.0168085.g003
Correlation of mTOR and p-mTOR with clinicopathological parameters

As shown in Table 6, no correlation was found between mTOR overexpression and any clinicopathological parameters, such as differentiation (OR = 1.59, 95% CI: 0.33–0.75, P = 0.56), depth of invasion (OR = 0.88, 95% CI: 0.59–1.31, P = 0.54), lymph node metastasis (OR = 1.72, 95% CI: 0.98–3.01, P = 0.06) or TNM stage (OR = 3.13, 95% CI: 0.72–13.61, P = 0.13).

The p-mTOR overexpression was strongly associated with depth of invasion (OR = 1.63, 95% CI: 1.08–2.45, P = 0.02, Fig 4a), and tumor stage (OR = 1.73, 95% CI: 1.29–2.32, P < 0.001, Fig 4b). The p-mTOR overexpression was independent of sex, age, differentiation, lymph node metastasis, and distant metastasis suggesting that p-mTOR was involved in tumor progression.

Correlation of mTOR and p-mTOR overexpression with OS

The survival time was extracted from the Kaplan–Meier survival curves analyzed by Enguage Digitizer software. In the present study, mTOR-positive expression was not correlated with the 1-, 3- and 5-year overall survival rate of the GC patients (Table 7). However, p-mTOR expression was significantly related to 1- (RR = 1.86, 95% CI: 1.50–2.31, P < 0.001, Fig 5a), 3- (RR = 1.71, 95% CI: 1.52–1.93, P < 0.001, Fig 5b), and 5-year (RR = 1.53, 95% CI: 1.26–1.86, P < 0.001, Fig 5c) OS in GC patients.

Sensitivity analysis and publication bias

In order to test the robustness of the RR estimates of OS, sensitivity analysis was conducted by individually excluding the studies and analyzing the effects on the remaining studies. As shown in Fig 6, the results of RR estimates were relatively reliable and credible as no point estimate of the omitted individual study was outside the 95% CI.

Begg’s rank correlation and Egger’s weighted regression methods were used to statistically assess the publication bias. As shown in Fig 7a and 7b, neither Begg’s (P = 0.23) nor Egger’s (P = 0.70) test provided any clear evidence of publication bias. These results indicate the absence of publication bias in the current study. We believe that the results of our meta-analysis are credible.
| Protein Study | Year | Number of Patient | Patient Sex | Age | Differentiation | Depth of invasion | LN metastasis | Metastasis | Tumor stage | Quality score |
|---------------|------|-------------------|-------------|-----|-----------------|------------------|--------------|------------|-------------|--------------|
| mTOR         | 2016 | 120               | male        | >60 | Well            | T1+T2            | Negative     | Positive   | I+II        | 60/13        |
| mTOR         | 2012 | 33                | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2009 | 1072              | male        | <60 | Poor            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2010 | 181               | female      | >60 | Well            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2015 | 396               | male        | >60 | Well            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2011 | 126               | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2009 | 1072              | male        | <60 | Poor            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2010 | 181               | female      | >60 | Well            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2015 | 396               | male        | >60 | Well            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2011 | 126               | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2009 | 1072              | male        | <60 | Poor            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2010 | 181               | female      | >60 | Well            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2015 | 396               | male        | >60 | Well            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2011 | 126               | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2009 | 1072              | male        | <60 | Poor            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2010 | 181               | female      | >60 | Well            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2015 | 396               | male        | >60 | Well            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2011 | 126               | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2009 | 1072              | male        | <60 | Poor            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2010 | 181               | female      | >60 | Well            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2015 | 396               | male        | >60 | Well            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2011 | 126               | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2009 | 1072              | male        | <60 | Poor            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2010 | 181               | female      | >60 | Well            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2015 | 396               | male        | >60 | Well            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2011 | 126               | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2009 | 1072              | male        | <60 | Poor            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2010 | 181               | female      | >60 | Well            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2015 | 396               | male        | >60 | Well            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2011 | 126               | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2009 | 1072              | male        | <60 | Poor            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2010 | 181               | female      | >60 | Well            | T3+T4            | Negative     | Negative   | III+IV      | NA           |
| mTOR         | 2015 | 396               | male        | >60 | Well            | T1+T2            | Negative     | Negative   | I+II        | 60/13        |
| mTOR         | 2011 | 126               | female      | <60 | Poor            | T3+T4            | Negative     | Negative   | III+IV      | NA           |

**GC:** gastric cancer; **NA:** not available. **TNM** stages are based on tumor-node-metastasis classification advocated by International Union against Cancer. Quality score: use the Newcastle-Ottawa scale (stars). 

**Table 5.** Clinicopathological parameters and quality scores of studies comparing mTOR/p-mTOR positive GC with mTOR/p-mTOR negative GC.

**Significances of p-mTOR in Gastric Cancer**

*PLOS ONE* | DOI:10.1371/journal.pone.0168085 | December 22, 2016

10/16
Discussion

The prognostic role of mTOR and p-mTOR expression has been studied extensively in other types of cancers, despite controversial results. Li et al. [24] first investigated the prognostic value of mTOR and p-mTOR in non-small cell lung (NSCLC) cancer comprehensively in a meta-analysis. In this study, no statistically significant association was found between mTOR and p-mTOR expression, and prognosis of NSCLC patients. The mTOR is a down-stream effector of PI3K-Akt signaling pathway and is regarded as a Ser/Thr protein kinase that mediates nutrient-dependent intracellular signaling related to cell growth, proliferation, and differentiation. Previous studies have identified mTOR signaling as a potential target for anti-cancer therapy using several cancer models [25]. Furthermore, the mTOR is activated and

Table 6. Meta-analysis of a putative association between clinicopathological parameters and mTOR, p-mTOR expression in GC.

| Protein | Parameters | Number of studies | Number of patients | Heterogeneity | Model | OR(95%CI) | P value |
|---------|------------|-------------------|--------------------|---------------|-------|-----------|---------|
| mTOR | Sex (male/female) | 4 | 1637 | 0 | 0.95 | FE | 1.16(0.94,1.43) | 0.17 |
| | Age (>60/<60) | 2 | 1192 | 88 | 0.004 | RE | 1.90(0.59,6.06) | 0.28 |
| | Differentiation (poor/well) | 3 | 1225 | 88 | 0 | RE | 1.59(0.33,7.57) | 0.56 |
| | Depth of invasion (T3+T4/T1+T2) | 3 | 1604 | 57 | 0.10 | RE | 0.88(0.59,1.31) | 0.54 |
| | LN (positive/negative) | 4 | 1637 | 74 | 0.01 | RE | 1.72(0.98,3.01) | 0.06 |
| | Metastasis (positive/negative) | 1 | 98 | — | — | — | 0.63(0.12,3.25) | 0.58 |
| | Tumor stage (III+IV/I+II) | 3 | 1225 | 89 | 0 | RE | 3.13(0.72,13.61) | 0.13 |
| p-mTOR | Sex (male/female) | 8 | 2994 | 0 | 0.60 | FE | 1.09(0.93,1.28) | 0.30 |
| | Age (>60/<60) | 5 | 2469 | 0 | 0.44 | FE | 1.46(1.24,1.72) | <0.001 |
| | Differentiation (poor/well) | 4 | 1663 | 75 | 0.01 | RE | 0.99(0.57,1.72) | 0.87 |
| | Depth of invasion (T3+T4/T1+T2) | 4 | 1751 | 54 | 0.06 | RE | 1.63(1.08,2.45) | 0.02 |
| | LN (positive/negative) | 7 | 2294 | 90 | 0 | RE | 1.57(0.83,2.98) | 0.17 |
| | Metastasis (positive/negative) | 2 | 246 | 58 | 0.12 | RE | 1.05(0.25,4.44) | 0.94 |
| | Tumor stage (III+IV/I+II) | 6 | 2595 | 58 | 0.04 | RE | 1.73(1.29,2.32) | <0.001 |

OR: odds ratio; CI: confidence interval; FE: fixed-effect model; RE: random-effect model; LN metastasis: lymph node metastasis

doi:10.1371/journal.pone.0168085.t006

Fig 4. Forrest plot of odds ratio for the association of p-mTOR overexpression and lymph node metastasis (4a), TNM stage (4b).

doi:10.1371/journal.pone.0168085.g004
phosphorylated (p-mTOR). Osaki et al. [26] reported that p-mTOR is frequently expressed in ovarian cancer and may be targeted to disrupt ovarian tumor cell growth. Association between mTOR and p-mTOR expression, and GC remains unclear. The role of mTOR and p-mTOR as prognostic predictors is controversial and warrants further investigation.

### Table 7. Meta-analysis of a putative association between OS and mTOR, p-mTOR expression in GC.

| Protein | OS       | Number of studies | Number of patients | Heterogeneity | Model | OR(95%CI)       | P value |
|---------|----------|-------------------|--------------------|---------------|-------|-----------------|---------|
| mTOR    | 1-year OS| 3                 | 1179               | 90            | RE    | 1.02(0.38,1.2.73) | 0.97    |
|         | 3-year OS| 3                 | 1179               | 89            | RE    | 1.06(0.62,1.81)  | 0.82    |
|         | 5-year OS| 3                 | 1179               | 94            | RE    | 1.02(0.65,1.61)  | 0.94    |
| p-mTOR  | 1-year OS| 7                 | 2269               | 0             | 0.75  | FE              | <0.001  |
|         | 3-year OS| 7                 | 2269               | 48            | 0.07  | FE              | <0.001  |
|         | 5-year OS| 7                 | 2269               | 70            | 0.003 | RE              | <0.001  |

OS: overall survival; RR: risk ratio; CI: confidence interval; FE: fixed-effect model; RE: random-effect model

doi:10.1371/journal.pone.0168085.t007

**Fig 5. Forrest plot of the risk ratio for the association of p-mTOR and OS.** (5a) Association between p-mTOR overexpression and 1-year OS. (5b) Association between p-mTOR overexpression and 3-year OS. (5c) Association between p-mTOR overexpression and 5-year OS.
doi:10.1371/journal.pone.0168085.g005

**Fig 6. Effect of individual studies on pooled risk ratios (RR) for p-mTOR expression and overall survival (OS) in patients with gastric cancer.**
doi:10.1371/journal.pone.0168085.g006
Interestingly, our original study demonstrated that both mTOR and p-mTOR were associated with several clinicopathological parameters such as TNM stage ($P < 0.05$). However, in the survival analysis, p-mTOR overexpression was significantly related to overall survival of GC patients ($P = 0.006$). No obvious difference was found between mTOR overexpression and OS in GC.

These inconsistent but interesting results require comprehensive investigation. Concurrently, because of limitations associated with small sample size, the meta-analysis was conducted to determine the prognostic value of mTOR and p-mTOR. Finally, in this meta-analysis, mTOR was not correlated with clinicopathological variables or OS. However, the correlation was found between depth of invasion and TNM stage, which are tumor predictors. Nonetheless, p-mTOR overexpression always indicates a shorter survival time in GC.

The mTOR has two main downstream factors, eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and ribosomal S6 kinase (p70S6K), which were mediated by phosphorylated mTOR activity [27]. Dephosphorylated 4E-BP1 binds to eukaryotic initiation factor 4E (eIF-4E), leading to inhibition of translation initiation. Phosphorylation of 4E-BP1 by p-mTOR releases 4E-BP1 from the mRNA cap-binding protein eIF4E, triggering the process of translation and protein synthesis [28, 29]. The p-mTOR activates p70S6K, and phosphorylated p70S6K combines with translation initiation complexes, to improve the efficiency of mRNA translation [30]. In general, p-mTOR induces phosphorylation of 4E-BP1 and P70S6K, and initiation of translation and protein synthesis. Yu et al. [18] reported that p-mTOR overexpression was related to clinicopathological variables and p-mTOR appears to be a more sensitive biomarker than total mTOR in predicting patient survival. Ji et al. [31] reported that targeting the expression of p-mTOR with specific siRNA reduced the growth and overall survival rate of Hela cervical cancer cells in vitro. The process of mTOR phosphorylation is suppressed by mTOR-specific inhibitors, such as everolimus and rapamycin. Phase II studies showed that treatment strategies using everolimus showed high efficacy and safety in GC, and therefore a global phase III study is currently underway [32]. Riquelme et al. [33] found that rapamycin treatment did not significantly alter the protein expression of total mTOR in several types of cell lines. However, rapamycin significantly decreased the phosphorylation of both mTOR and its downstream effectors, such as p70S6K1 and 4E-BP1. In a previous study [34], Yang and his co-workers used Western blot and reverse transcription polymerase chain reaction (RT-PCR) to assess the expression of mTOR in GC. The findings suggest that the expression of mTOR at
the protein level was significantly lower than in the corresponding normal gastric mucosa, while the ratio of p-mTOR was significantly increased in tumor tissues. The conclusion was that the mTOR signaling pathway was activated in GC, mainly via increased mTOR phosphorylation rather than overexpression of dephosphorylated mTOR. In our original survival analysis, the results indicated that p-mTOR overexpression was significantly associated with overall survival rate. However, the mTOR expression and TNM stage were meaningless. Furthermore, in this meta-analysis, we arrived at a similar conclusion suggesting that p-mTOR plays a key role in GC as a promising predictor.

However, the limitations of the current study include: (1) small number of patients; (2) exclusion of a few eligible non-English and non-Chinese studies; and (3) insufficient number of articles. However, several advantages were as follows: (1) This is the first available study and meta-analysis of the association between mTOR, p-mTOR overexpression and clinicopathological parameters in GC. (2) We also compared the prognostic value of mTOR and p-mTOR in GC for the first time. (3) The results of this study provide theoretical support of rapamycin treatment in GC.

In summary, it is not possible to accurately predict the prognosis of GC patients on the basis of the current staging system alone. The expression of p-mTOR is significantly associated with clinicopathological parameters and OS, and plays a vital role in the progression of GC. It is a more valuable prognostic factor than mTOR in GC and may be regarded as a new predictor.

Supporting Information

S1 File. PRISMA Checklist. PRISMA 2009 checklist.
(DOC)

S2 File. Ethics Certification.
(DOCX)

Author Contributions

Conceptualization: GDC.
Data curation: GDC XYX JWZ.
Formal analysis: GDC.
Funding acquisition: BC MMX.
Investigation: GDC XYX BC.
Methodology: BC GDC.
Project administration: BC MMX.
Resources: GDC JWZ.
Software: BC GDC.
Validation: MMX.
Visualization: GDC.
Writing – original draft: GDC.
Writing – review & editing: BC MMX.
References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jamal A, et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65: 87–108. doi: 10.3322/caac.21262 PMID: 25651787

2. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for GC. N Engl J Med 359: 453–462.

3. Zou WB, Yang F, Li ZS (2015) How to improve the diagnosis rate of early gastric cancer in China. Zhejiang Da Xue Xue Bao Yi Xue Ban 44: 9–14. PMID: 25851969

4. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137–2150. doi: 10.1200/JCO.2005.05.2308 PMID: 16682732

5. Niu HY, Wang JH, Li H, He P (2011) Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Canc Res 30: 28.

6. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, et al (2001) The phosphatidylinositol3-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426–7429. PMID: 11606375

7. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424–430. doi: 10.1038/nature04869 PMID: 16724053

8. Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F (2013) Targeting the PI3-kinase/ Akt/mTOR signaling pathway. Surg Oncol Clin N Am 22: 641–664. doi: 10.1016/j.soc.2013.06.008 PMID: 24012393

9. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485: 55–61. doi: 10.1038/nature10912 PMID: 22367541

10. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501. doi: 10.1038/nrcc839 PMID: 12094235

11. Xu DZ, Geng OR, Tian Y, Cai MY, Fang XJ, Zhan YQ, et al (2010) Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer 10: 536. doi: 10.1186/1471-2407-10-536 PMID: 20929525

12. Wang D, Chen J, Guo F, Chen H, Duan Z, Wei MY, et al (2011) Clinical Significance of mTOR and p-mTOR Protein Expression in Human Colorectal Carcinomas. Asian Pac J Cancer Prev 12: 2581–2584. PMID: 22320958

13. Ahn HS, Lee HJ, Hahn S, Kim WH, Lee KU, Sano T, et al (2010) Evaluation of the seventh American Joint Committee on Cancer/International Union Against Cancer Classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer 116: 5592–5598. doi: 10.1002/cncr.25550 PMID: 20737569

14. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, et al (2009) Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res 15: 7207–7216. doi: 10.1158/1078-0432.CCR-09-1249 PMID: 19934294

15. Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysis. Eur J Epidemiol 25: 603–605. doi: 10.1007/s10654-010-9491-z PMID: 20652370

16. Li M, Song L, Gao X, Chang W, Qin X (2012) Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncology letters 4: 1213–1218. doi: 10.3892/ol.2012.930 PMID: 23052120

17. Xiao L, Wang YC, Li WS, Du Y (2009) The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 28: 152. doi: 10.1186/1756-9966-28-152 PMID: 20033885

18. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, et al (2009) Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer. Clin Cancer Res 15: 1821–1829. doi: 10.1158/1078-0432.CCR-08-2138 PMID: 19223493

19. Inokuchi M, Murayama T, Hayashi M, Takagi Y, Kato K, Enjoji M, et al (2011) Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer. Exp Ther Med 2: 251–256. doi: 10.3892/etm.2011.187 PMID: 22977493

20. An JY, Kim KM, Choi MG, Noh JH, Sohn TS, Bae JM, et al (2010) Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer 126: 2904–2913. doi: 10.1002/ijc.24872 PMID: 19739122

21. Bian Y, Wang Z, Xu J, Zhao W, Cao H, Zhang Z (2015) Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer. Biochem Biophys Res Commun 464: 534–540. doi: 10.1016/j.bbrc.2015.07.001 PMID: 26159923
22. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, et al (2009) Relation between outcomes and localization of p-mTOR expression in gastric cancer. Br J Cancer 100: 782–788. doi: 10.1038/sj.bjc.6604915 PMID: 19223902

23. Byeon SJ, Han N, Choi J, Kim MA, Kim WH (2014) Prognostic Implication of TSC1 and mTOR Expression in Gastric Carcinoma. J Surg Oncol 109: 812–817. doi: 10.1002/jso.23585 PMID: 24615476

24. Li L, Liu D, Oiu ZX, Zhao S, Zhang L, Li WM (2015) The Prognostic Role of mTOR and P-mTOR for Survival in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS One 10: e0116771. doi: 10.1371/journal.pone.0116771 PMID: 25680114

25. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671–688. doi: 10.1038/nrd2062 PMID: 16883305

26. Osaki M, Kase S, Adachi K, Takeda A, Hashimoto K, Ito H (2004) Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol 130: 8–14. doi: 10.1007/s00432-003-0505-z PMID: 14605879

27. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, et al (2004) Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. Clin Cancer Res 10: 6779–6788. doi: 10.1158/1078-0432.CCR-04-0112 PMID: 15501954

28. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105:17414–17419. doi: 10.1073/pnas.0809136105 PMID: 18955708

29. Oulhen N, Mulner-Lorillon O, Cormier P (2010) eIF4E-binding proteins are differentially modified after ammonia versus intracellular calcium activation of sea urchin unfertilized eggs Mol Reprod Dev 77: 83–91. doi: 10.1002/mrd.21110 PMID: 19777548

30. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J (1998) Amino Acid Sufficiency and mTOR Regulate p70 S6 Kinase and eIF-4E BP1 through a Common Effector Mechanism. Biol Chem 273: 14484–14494.

31. Ji J, Zheng PS (2010) Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol 117: 103–108. doi: 10.1016/j.ygyno.2009.12.020 PMID: 20102778

32. Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY, et al (2012) Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer 106: 1039–1044. doi: 10.1038/bjc.2012.47 PMID: 22343617

33. Riquelme I, Tapia O, Espinoza JA, Leal P, Buchegger K, Sandoval A, et al (2016) The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines. Pathol Oncol Res [Epub ahead of print].

34. Yang HY, Xue LY, Xing LX, Wang J, Wang JL, Yan X, et al (2013) Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma. Mol Med Rep 7: 537–542. doi: 10.3892/mmr.2012.1208 PMID: 23229050